eu-japan.com
Sosei Group acquires Cambridge/UK based Heptares Therapeutics Ltd for up to US$ 400 million
Sosei Group acquires candidate drugs to compensate for expected loss of patent protection for the Seebri inhaler in 2026 Heptares Therapeutics Ltd emerged from the MRC Laboratory of Molecular Biolo…